Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment
Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
泰和誠醫療服務控股有限公司（"泰和誠醫療" 或 "公司")（紐交所:CCM），一家專門從事癌症治療、研究、教育和預防的醫療機構，在中國廣州，今天宣佈該公司的子公司廣州泰和誠癌症中心（"廣州醫院"）已獲得了其質子設備的大型醫療設備採購許可證（"許可證").
As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Hospital has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently submitted the application for the License for such proton equipment, planning to offer proton therapy treatment services at its proton center. On September 14, 2024, the National Health Commission of the PRC announced to grant approval to Guangzhou Hospital's application for the License. Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.
正如泰和誠醫療在2023年12月31日結束的財政年度年度報告中披露的，廣州醫院已於2020年9月完成了質子設備的安裝，並於2022年11月開始了臨床試驗。廣州醫院隨後提交了質子設備許可證的申請，計劃在其質子中心提供質子治療服務。2024年9月14日，中國國家衛生健康委員會宣佈批准了廣州醫院對許可證的申請。廣州醫院計劃在必要的準備工作後儘快開始其質子治療服務。
譯文內容由第三人軟體翻譯。